Alnair Therapeutics
Chicago · Founded 2022
About Alnair Therapeutics
Alnair Therapeutics is a preclinical stage precision oncology platform focusing on developing innovative approaches to treat difficult-to-treat malignancies. It has created a first-of-its-kind drug delivery technology that uses the unique features of cancer metabolism to improve drug targeting and penetration directly into cancer cells, hence enhancing patient treatment outcomes.
Company Facts
- Founded: 2022
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $1.8M
- Funding stage: Seed
- Last round: Pre-Seed (Jun 2023)
Industries & Categories
Biotechnology, Oncology
Social Profiles
Canonical: https://fsome.com/organization/alnair-therapeutics-84772 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.